Cryoglobulinemia and Emerging Related Disorders

Cryoglobulinemia refers to the presence of cryoglobulins in the serum, which are specific immunoglobulins precipitating at temperatures below 37 °C. Type I cryoglobulinemia involves a single isotype of monoclonal immunoglobulin. Conversely, type II and type III cryoglobulinemia, categorized as mixed cryoglobulinemia, include both immunoglobulin G (IgG) and immunoglobulin M (IgM). Mixed cryoglobulinemia is often associated with various lymphoproliferative, viral, and autoimmune disorders, predominantly linked to the hepatitis C virus (HCV) in many cases. The core mechanism involves B-cell proliferation and autoantibody production. This condition may lead to systemic vasculitis, displaying symptoms that range from purpura, arthralgia, and weakness to severe manifestations like skin ulcers, neurological issues, and renal involvement. This chapter focuses on mixed cryoglobulinemia, which is characterized by diverse clinical presentations and a prognosis largely determined by the extent of vasculitis-related multiorgan damage. It is noteworthy that the linked underlying condition significantly affects mortality and morbidity rates. Managing cryoglobulinemic vasculitis requires a tailored approach, considering the related condition and organ involvement. Treatment typically involves a combination of antiviral therapy (in HCV cases), immunosuppressive drugs, and immunotherapy, often highlighting anti-CD20 B-cell depletion therapies.